Search results

  1. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury

  2. Assessing motility of the gastrointestinal tract using a wireless capsule (IPG502)

    Evidence-based recommendations on assessing motility of the gastrointestinal (GI) tract using a wireless capsule to investigate motility disorders

  3. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products

  4. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (IPG498)

    Evidence-based recommendations on powdered micodebrider turbinoplasty for inferior turbinate hypertrophy (swollen ridges in the nose)

  5. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (IPG496)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia

  6. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  7. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

    Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting in coronary artery disease (CAD)

  8. Radiofrequency tissue reduction for turbinate hypertrophy (IPG495)

    Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy (swollen ridges in the nose that narrow the nasal passage)

  9. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

     April 2020: This guidance has been withdrawn while the MHRA conducts an investigation into the MAGEC system. The MHRA issued a Medical Device Alert MDA/2020/011 for all MAGEC systems. This is in response to the manufacturer’s latest Field Safety Notice and previous field safety notices for problems that may require early removal of devices and lead to inadequate treatment. The MHRA is not recommending prophylactic removal of devices but the supply of all MAGEC systems is suspended in the UK while the MHRA investigation is ongoing. The MHRA has set out the following actions: Do not implant MAGEC rods in the UK until further notice. Identify all patients implanted with a MAGEC System and ensure systems are in place to follow up these patients.

  10. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (IPG487)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis (excess sweating) of the upper limb (palm of hand and armpit)

  11. Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee (IPG493)

    Evidence-based recommendations on arthroscopic radiofrequency chondroplasty for discrete chondral defects of the articular cartilage in the knee

  12. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose

  13. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)

    Evidence-based recommendations on transoral carbon dioxide (CO2) laser surgery for primary treatment of oropharyngeal malignancy (throat cancer)

  14. Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from

  15. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma (BCC) and primary squamous cell carcinoma (SCC) (skin cancer)

  16. Optical coherence tomography to guide percutaneous coronary intervention (IPG481)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention (near-infrared light for artery imaging)

  17. Endoscopic thoracic sympathectomy for primary facial blushing (IPG480)

    Evidence-based recommendations on endoscopic thoracic sympathectomy (cutting off nerve signals to stop blushing) for primary facial blushing

  18. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)

    Evidence-based recommendations on prostatic urethral lift implants to treat lower tract symptoms secondary to benign prostate hyperplasia (enlarged prostate)

  19. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (IPG472)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale (PFO/hole in the heart) to prevent recurrent cerebral embolic events

  20. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    Evidence-based recommendations on ultra-radical (extensive) surgery for advanced ovarian cancer (removing cancerous tissue from all organs)

  21. Implantation of a duodenal–jejunal bypass sleeve for managing obesity (IPG471)

    Evidence-based recommendations on the implantation of a duodenal–jejunal bypass sleeve (temporary implant in the gut) for managing obesity

  22. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative